Fairvalue-Calculator Fairvalue-Calculator
EN DE

Repligen Corporation (RGEN) Fair Value & Analysis

Healthcare · US · Market cap $7.1B

Price$126.37
Fair Value$25.29
Upside-80.0%
Quality95/100
Evidence: High Range $21.09 – $25.29

Fair value as of: Jun 24, 2026

Analysis

Repligen Corporation (RGEN) currently trades at $126.37, while our model-based Fair Value estimate is $25.29 — implying the stock looks roughly 80.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCe…

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is Repligen Corporation (RGEN) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $25.29 versus a price of $126.37 — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RGEN?
Our 21-model fair value for Repligen Corporation is $25.29 (as of Jun 24, 2026), built from audited fundamentals. The current price is $126.37.
What is the quality score of RGEN?
Repligen Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.